Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: To evaluate the long-term efficacy and safety of three-monthly paliperidone palmitate (PP3M) in Asian patients with stable schizophrenia in a naturalistic setting. Methods: Asian patients recruited between May 2016 and March 2018 from the prospective, single-arm, non-randomized, open-label, multi-national REMISSIO study were analyzed. Patients received PP3M over 12 months following ≥ 4 months of treatment with one-monthly paliperidone palmitate. The primary efficacy endpoint was the proportion of patients who achieved symptomatic remission. Other endpoints were changes in Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) total scores, hospitalization rates, and safety. Results: A total of 71 patients (23.3%) were Asian (South Korea: 33, Malaysia: 21, Taiwan: 17); 95.8% of patients completed the study. At LOCF, 71% of Asian patients achieved symptomatic remission compared to the overall population (n = 172/303, 56.8%). Improvements in mean (standard deviation) PANSS and PSP total scores from baseline to LOCF in Asian patients and overall population were clinically significant. A lower proportion of Asian patients had ≥ 1 psychiatric hospitalization after PP3M treatment (n = 1/70, 1.4%) than during the 12 months before (n = 12/70, 17.1%); compared with patients in the overall population after (n = 8/303, 2.6%) and before PP3M treatment (n = 37/303, 12.2%). The overall incidence of treatment-emergent adverse events across Asian patients was 62.9% compared to 53.1% in the overall population. Safety findings were consistent with the known safety profile of PP3M. Conclusion: Our findings confirm existing evidence on the efficacy and tolerability of PP3M in Asian patients with stable schizophrenia over 12 months of treatment.
Abstract
Objective: To evaluate the long-term efficacy and safety of three-monthly paliperidone palmitate (PP3M) in Asian patients with stable schizophrenia in a naturalistic setting. Methods: Asian patients recruited between May 2016 and March 2018 from the prospective, single-arm, non-randomized, open-label, multi-national REMISSIO study were analyzed. Patients received PP3M over 12 months following ≥ 4 months of treatment with one-monthly paliperidone palmitate. The primary efficacy endpoint was the proportion of patients who achieved symptomatic remission. Other endpoints were changes in Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) total scores, hospitalization rates, and safety. Results: A total of 71 patients (23.3%) were Asian (South Korea: 33, Malaysia: 21, Taiwan: 17); 95.8% of patients completed the study. At LOCF, 71% of Asian patients achieved symptomatic remission compared to the overall population (n = 172/303, 56.8%). Improvements in mean (standard deviation) PANSS and PSP total scores from baseline to LOCF in Asian patients and overall population were clinically significant. A lower proportion of Asian patients had ≥ 1 psychiatric hospitalization after PP3M treatment (n = 1/70, 1.4%) than during the 12 months before (n = 12/70, 17.1%); compared with patients in the overall population after (n = 8/303, 2.6%) and before PP3M treatment (n = 37/303, 12.2%). The overall incidence of treatment-emergent adverse events across Asian patients was 62.9% compared to 53.1% in the overall population. Safety findings were consistent with the known safety profile of PP3M. Conclusion: Our findings confirm existing evidence on the efficacy and tolerability of PP3M in Asian patients with stable schizophrenia over 12 months of treatment.
참고문헌 (42)
- Nash AI, "Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation", Neuropsychiatr Dis Treat, 15, pp.731~737 (2019)
- Higashi K, "Medication adherence in schizophrenia : factors influencing adherence and consequences of nonadherence, a systematic literature review", Ther Adv Psychopharmacol, 3, pp.200~218 (2013)
- Haddad PM, "Nonadherence with antipsychotic medication in schizophrenia : challenges and management strategies", Patient Relat Outcome Meas, 5, pp.43~62 (2014)
- Chapman SC, "Medication nonadherence and psychiatry", Curr Opin Psychiatry, 26, pp.446~452 (2013)
- Novick D, "Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia", Psychiatry Res, 176, pp.109~113 (2010)
- Savitz AJ, "Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study", Int J Neuropsychopharmacol, 19, pp.pyw018~ (2016)
- Lopez A, "Role of paliperidone palmitate 3-monthly in the management of schizophrenia : insights from clinical practice", Neuropsychiatr Dis Treat, 15, pp.449~456 (2019)
- Johnson DA, "Historical perspective on antipsychotic long-acting injections", Br J Psychiatry Suppl, 52, pp.S7~S12 (2009)
- Bossie CA, "Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia : pragmatic versus explanatory study designs", Int Clin Psychopharmacol, 30, pp.272~281 (2015)
- Anderson JP, "Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations", BMC Psychiatry, 17, pp.346~ (2017)
- Olivares JM, "Definitions and drivers of relapse in patients with schizophrenia : a systematic literature review", Ann Gen Psychiatry, 12, pp.32~ (2013)
- Taylor M, "Impact of risperidone long acting injection on resource utilization in psychiatric secondary care", J Psychopharmacol, 22, pp.128~131 (2008)
- Lehman AF, "American Psychiatric Association;Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
- Schreiner A, "Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia", Schizophr Res, 169, pp.393~399 (2015)
- Tiihonen J, "Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia", JAMA Psychiatry, 74, pp.686~693 (2017)
- Alphs L, "Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia : a randomized, open-label, review boardblinded 15-month study", J Clin Psychiatry, 76, pp.554~561 (2015)
- Gopal S, "Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia", Curr Med Res Opin, 31, pp.2043~2054 (2015)
- Berwaerts J, "Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia : a randomized clinical trial", JAMA Psychiatry, 72, pp.830~839 (2015)
- Bauer SM, "Culture and the prevalence of hallucinations in schizophrenia", Compr Psychiatry, 52, pp.319~325 (2011)
- Garcia-Portilla MP, "Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia", Ther Adv Psychopharmacol, 10, pp.2045125320926347~ (2020)
- Andreasen NC, "Remission in schizophrenia : proposed criteria and rationale for consensus", Am J Psychiatry, 162, pp.441~449 (2005)
- Study of paliperidone palmitate 3 month and 1 month formulations for the treatment of patients with schizophrenia, "Janssen Research & Development", National Library of Medicine, ~, pp.NCT01515423 (2016)
- Harrington D, "New guidelines for statistical reporting in the journal", N Engl J Med, 381, pp.285~286 (2019)
- Haro JM, "Understanding the course of persistent symptoms in schizophrenia : longitudinal findings from the pattern study", Psychiatry Res, 267, pp.56~62 (2018)
- Savitz AJ, "Efficacy and safety of paliperidone palmitate threemonthly formulation in East Asian patients with schizophrenia : subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study", Neuropsychiatr Dis Treat, 13, pp.2193~2207 (2017)
- Hayhurst KP, "Improved quality of life over one year is associated with improved adherence in patients with schizophrenia", Eur Psychiatry, 29, pp.191~196 (2014)
- Masand PS, "Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia : a review", Prim Care Companion J Clin Psychiatry, 11, pp.147~154 (2009)
- Fleischhacker WW, "Treatment of schizophrenia with long-acting injectable risperidone : a 12-month open-label trial of the first long-acting second-generation antipsychotic", J Clin Psychiatry, 64, pp.1250~1257 (2003)
- Lee NY, "A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea", Int Clin Psychopharmacol, 29, pp.279~287 (2014)
- Mihaljevic-Peles A, "Remission and employment status in schizophrenia and other psychoses : one-year prospective study in Croatian patients treated with risperidone long acting injection", Psychiatr Danub, 28, pp.263~272 (2016)
- Rossi A, "Remission in schizophrenia : one-year Italian prospective study of risperidone long-acting injectable(RLAI)in patients with schizophrenia or schizoaffective disorder", Hum Psychopharmacol, 24, pp.574~583 (2009)
- Yuan-Hwa Chou, "A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 13(2), pp.121~128 (2015), 대한정신약물학회
- Emsley R, "Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia : an evidence-based review", Neuropsychiatr Dis Treat, 14, pp.205~223 (2018)
- Lafeuille MH, "Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics", Am J Health Syst Pharm, 72, pp.378~389 (2015)
- Greene M, "Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder", J Med Econ, 21, pp.127~134 (2018)
- Joshi K, "Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits", J Comp EffRes, 7, pp.121~133 (2018)
- Titus-Lay EN, "Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis", Ment Health Clin, 8, pp.56~62 (2018)
- Pfeiffer PN, "Dosing frequency and adherence to antipsychotic medications", Psychiatr Serv, 59, pp.1207~1210 (2008)
- Brasso C, "Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia", Neuropsychiatr Dis Treat, 13, pp.2767~2779 (2017)
- Mathews M, "Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia", Neuropsychiatr Dis Treat, 15, pp.1365~1379 (2019)
- Arteaga C, "Assessing the cost-effectiveness of three-monthly paliperidone palmitate versus its prior monthly formulation for the management of schizophrenia in the UK setting", Value Health, 21(Suppl 1), pp.S185~ (2018)
- Emond B, "Adherence, healthcare resource utilization, and costs in medicaid beneficiaries with schizophrenia transitioning from once-monthly to once-every-3-months paliperidone palmitate", Pharmacoecon Open, 3, pp.177~188 (2019)